T. Gunawardena

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator

Onofrio Laselva, Claire Bartlett, T. Gunawardena et al. · European Respiratory Journal · 2020 · 164 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation

Ido Sadras, Eitan Kerem, Galit Livnat et al. · Journal of Cystic Fibrosis · 2023 · 53 citations · Full text

Medicine, Molecular Genetics, Pharmacotherapy +12

A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients

Jia Xin Jiang, Leigh Wellhauser, Onofrio Laselva et al. · Stem Cell Reports · 2021 · 40 citations · Full text

Life Sciences, Cell Biology, Molecular Medicine +16

Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants

Onofrio Laselva, Claire Bartlett, Alec Popa et al. · Journal of Cystic Fibrosis · 2020 · 39 citations · Full text

Life Sciences, Genetics, Molecular Genetics +5

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor

Onofrio Laselva, Theo J. Moraes, Gengming He et al. · Journal of Personalized Medicine · 2020 · 31 citations · Full text

Medicine, Molecular Genetics, Pharmacology +16